Other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS)

Page last updated: 24 May 2018

Instructions for PDF forms

The PDF forms on this page may not open correctly in your browser. Please download the form to your computer before editing.

Life Saving Drugs Program (LSDP)

The Australian Government provides fully subsidised access for eligible patients to expensive and life saving medicines for very rare and life-threatening medical conditions through the LSDP.

To apply on behalf of a patient, the treating physician must complete the initial application form, provide copies of all test results as evidence, and submit a clinic letter and email the completed excel spreadsheet.

For ongoing treatment, the treating physician must submit the separate reapplication form along with copies of all test results as evidence of ongoing eligibility and the completed excel spreadsheet to the LSDP by 1 May every year to continue to receive subsidised treatment through the LSDP.

LSDP Funding Criteria and Conditions

Subsidised access through the LSDP is granted in accordance with specified eligibility criteria and subject to certain conditions:
Life Saving Drugs Program Criteria and Conditions.

Before being considered for inclusion, a drug must first be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) and rejected on the basis of cost effectiveness. The Chief Medical Officer (CMO) advises the Minister for Health on drugs proposed to be included on the LSDP.

Medicines currently funded through the LSDP

There are currently thirteen medicines available to eligible patients for the treatment of nine conditions. To view the Guidelines and application forms, visit:
  1. Imiglucerase (Cerezyme®), Velaglucerase (VPRIV®), Taliglucerase (Elelyso®) and Miglustat (Zavesca®) for the treatment of Gaucher disease (Type 1)
  2. Agalsidase alfa (Replagal®) and Agalsidase beta (Fabrazyme®) for the treatment of Fabry disease
  3. Laronidase (Aldurazyme®) for the treatment of Mucopolysaccharidosis Type I (MPS I)
  4. Idursulfase (Elaprase®) for the treatment of Mucopolysaccharidosis Type II (MPS II)
  5. Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IVA (MPSIVA)
  6. Galsulfase (Naglazyme®) for the treatment of Mucopolysaccharidosis Type VI (MPS VI)
  7. Alglucosidase alfa (Myozyme®) for the treatment of Infantile-onset, Juvenile Late-onset or Adult Late-onset Pompe disease
  8. Eculizumab (Soliris®) for the treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)
  9. Nitisinone (Orfadin®) for the treatment of Hereditary Tyrosinaemia Type I (HTI)
For information regarding the management and dispensing of these expensive life saving drugs, please view the Drug Supply Fact Sheet (PDF 384 KB), Drug Supply Fact Sheet (Word 510 KB).

1. Imiglucerase (Cerezyme®), Velaglucerase (VPRIV®), Taliglucerase (Elelyso®) and Miglustat (Zavesca®) for the treatment of Gaucher disease (Type 1)

2. Agalsidase alfa (Replagal®) and Agalsidase beta (Fabrazyme®) for the treatment of Fabry Disease

3. Laronidase (Aldurazyme®) for the treatment of Mucopolysaccharidosis Type I (MPS I)

4. Idursulfase (Elaprase®) for the treatment of Mucopolysaccharidosis Type II (MPS II)

5. Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IVA (MPSIVA)

6. Galsulfase (Naglazyme®) for the treatment of Mucopolysaccharidosis Type VI (MPS VI)

7. Alglucosidase alfa (Myozyme®) for the treatment of Infantile-onset, Juvenile Late-onset or Adult Late-onset Pompe Disease

8. Eculizumab (Soliris®) for the treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)

9. Nitisinone (Orfadin®) for the treatment of Hereditary Tyrosinaemia Type I


Review of the LSDP

On 28 January 2018 the Minister for Health, the Hon Greg Hunt MP, announced the outcomes of the Review of the LSDP and provided the Government response.

These documents are available at Review of the Life Saving Drugs Program (LSDP).

Agreement with Industry

The Government and Medicines Australia (MA), on behalf of sponsors of medicines on the LSDP, have entered into an agreement to implement reforms to the program following the January 2018 Government response to the Review of the LSDP. This Compact was agreed on 8 May 2018.

The agreement with MA will provide policy stability, transparency and certainty for industry and the rare diseases medicines sector. The agreement enables savings to Government through price reductions for medicines funded through the LSDP, and supports the introduction of broader policies similar to Pharmaceutical Benefits Scheme (PBS) medicines.

The Government will continue to consult with key stakeholders in implementing the improvements as outlined in the agreement.

LSDP Agreement between the Government and Medicines Australia (PDF 378KB) - (Word 27KB)

Further Information

Life Saving Drugs Program
Phone: (02) 6289 2336
Fax: (02) 6289 8537
Email: LSDP team